Fuji Pharma Co., Ltd. (TYO:4554)
Japan · Delayed Price · Currency is JPY 1,857.00
-21.00 (-1.12%)
Nov 13, 2026, 3:30 PM JST
Fuji Pharma Financials Overview
Financials in millions JPY. Fiscal year is October - September.
Millions JPY. Fiscal year is Oct - Sep.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Revenue Revenue Growth | 62,386 | 62,386 | 51,677 | 46,138 | 40,889 | 35,426 |
Revenue Growth | 20.72% | 20.72% | 12.01% | 12.84% | 15.42% | 4.23% |
Gross Profit Gross Profit Growth | 24,321 | 24,321 | 20,763 | 17,844 | 16,515 | 14,559 |
Operating Income Operating Income Growth | 6,355 | 6,355 | 4,990 | 3,881 | 3,859 | 3,778 |
Net Income Net Income Growth | 2,831 | 2,831 | 3,000 | 6,146 | 3,435 | 2,696 |
Earnings Per Share EPS Growth | 111.18 | 111.18 | 122.93 | 252.81 | 141.35 | 110.98 |
EPS Growth | -9.56% | -9.56% | -51.37% | 78.86% | 27.37% | 22.60% |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Cash & Investments Cash & Investments Growth | 9,496 | 9,496 | 7,245 | 4,585 | 2,324 | 3,546 |
Total Debt Total Debt Growth | 28,373 | 28,373 | 30,937 | 29,254 | 28,948 | 24,569 |
Net Cash (Debt) Net Cash Growth | -18,877 | -18,877 | -23,692 | -24,669 | -26,624 | -21,023 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -741.32 | -741.32 | -970.86 | -1014.74 | -1095.58 | -865.39 |
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 6,174 | 6,174 | 5,801 | 4,151 | 1,917 | -658 |
Capital Expenditures CapEx Growth | -2,092 | -2,092 | -1,981 | -2,778 | -3,327 | -5,097 |
Free Cash Flow Free Cash Flow Growth | 4,082 | 4,082 | 3,820 | 1,373 | -1,410 | -5,755 |
Free Cash Flow Growth | 6.86% | 6.86% | 178.22% | - | - | - |
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 30, 2026 | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Gross Margin | 38.98% | 38.98% | 40.18% | 38.67% | 40.39% | 41.10% |
Operating Margin | 10.19% | 10.19% | 9.66% | 8.41% | 9.44% | 10.66% |
Pretax Margin | 5.06% | 5.06% | 7.74% | 17.93% | 10.76% | 10.51% |
Profit Margin | 4.54% | 4.54% | 5.80% | 13.32% | 8.40% | 7.61% |
FCF Margin | 6.54% | 6.54% | 7.39% | 2.98% | -3.45% | -16.25% |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 15, 2026 | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
Dividend Per Share Dividend Per Share Growth | 49.000 | - | 45.500 | 42.500 | 37.000 | 35.000 |
Dividend Per Share Growth | 14.29% | - | 7.06% | 14.87% | 5.71% | 20.69% |
Dividend Yield | 2.64% | - | 2.95% | 3.34% | 3.17% | 3.38% |
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
| Period Ending | Nov '26 Nov 15, 2026 | Sep '26 Sep 30, 2026 | Sep '25 Sep 30, 2025 | Sep '24 Sep 30, 2024 | Sep '23 Sep 30, 2023 | Sep '22 Sep 30, 2022 |
PE Ratio | 16.70 | 16.51 | 12.57 | 5.04 | 8.25 | 9.32 |
Forward PE | 10.23 | 10.08 | 10.31 | 7.24 | 8.29 | 8.47 |
P/FCF Ratio | 11.88 | 11.45 | 9.87 | 22.54 | - | - |
PS Ratio | 0.78 | 0.75 | 0.73 | 0.67 | 0.69 | 0.71 |